Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isonicotinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.52 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonicotinic Acid SCHEMBL2197 | 1.00 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL1108 | 0.97 | — | — | |
| Isonicotinic Acid SCHEMBL1414914 | 0.97 | NAPRT (1.00) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25271512 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25219686 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25261208 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25270920 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL15401690 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25273146 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25222705 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429349-B | Preparation method of heterogeneous catalytic 2-trifluoromethyl substituted benzimidazole compound | 杭州职业技术学院 | 2022-12-20 | — | — | CN | claimed |
| EP-0333427-B1 | Heterocyclic derivatives | SMITHKLINE BEECHAM FARMA (IT) | 1995-08-23 | — | — | EP | claimed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | claimed |
| JP-62153272-A | — | — | None | — | — | JP | disclosed |
| CN-119930508-A | Photoacid generator method for producing same Photoresist composition containing the photoacid generator | 国科天骥(山东)新材料有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-117964555-A | Bisamide derivative containing phenyl ether bond, and preparation method and application thereof | 南开大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-117903168-A | Pyrrolo [2,3-d ] thiazole derivatives, and preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-113272309-B | Tricyclic inhibitors of hepatitis b virus | 圣拉斐尔医院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117343077-A | Isoindolinone morpholine derivative and preparation method and application thereof | 南开大学 | 2024-01-05 | — | — | CN | disclosed |
| US-4447434-A | ANTIULCER, ANTISECRETORY, OR ANTICHOLINERGIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-05-08 | — | — | US | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4424226-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0074628-A2 | Ascochlorin derivatives; process for preparing the same and pharmaceutical composition containing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4035413-A | ANTIALLERGENS, ANTILIPAEMIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-4013719-A | ANTILIPEMIC, ANTIALLERGEN | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-4000183-A | ANTIALLERGENS AND HYPOLIPIDAEMIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000144-A | HYPOLIPIDAEMIC AGENTS AND ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3933835-A | ANTIALLERGENS, HYPOLIPIDAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |